InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment
New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model SCHLIEREN , SWITZERLAND, April 14, 2026 /EINPresswire.com/ -- New Offering Integrates DOPPL’s Patient-Derived Intestinal …